A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT06465329

Public ClinicalTrials.gov record NCT06465329. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 25, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer

Study identification

NCT ID: NCT06465329
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Non-Small Cell Lung Cancer

Interventions

Cemiplimab Drug
Platinum-based chemotherapy Drug
REGN7075 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 17, 2024
Primary completion: May 19, 2027
Completion: May 1, 2030
Last update posted: Jul 7, 2026

2024 – 2030

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of California Irvine	Orange	California	92868	Recruiting
Orchard Healthcare Research Inc.	Skokie	Illinois	60077	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Detroit Clinical Research Center	Farmington Hills	Michigan	48334	Recruiting
Morristown Medical Center	Morristown	New Jersey	07960	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Recruiting
Oncology Hematology Care Clinical Trials LLC	Cincinnati	Ohio	45245	Recruiting
Providence Portland Medical Center	Portland	Oregon	97213	Recruiting
University Of Nebraska Medical Center	Portland	Oregon	97213	Recruiting
Lifespan Cancer Institute	Providence	Rhode Island	02903	Recruiting
Prairie Lakes Healthcare System	Watertown	South Dakota	57201	Recruiting
University of Tennessee Medical Center	Knoxville	Tennessee	37920	Recruiting
Sarah Cannon Research Institute (SCRI) Oncology Partners	Nashville	Tennessee	37203	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
BRCC/Oncology & Hematology Associates of SW Virginia	Blacksburg	Virginia	24060	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06465329, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 7, 2026 · Synced Jul 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06465329 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →